Abstract
Using short peptide fragments of proteins to elicit antibodies able to recognize the protein from which the peptide sequence was derived, is one of the main goals in immunotherapy today. Indeed, peptide-immunotherapy appears as an obliged way to obtain antibodies of predetermined specificity and exempt from the complications associated with whole cells/entire protein vaccines. However, effective peptide-immunotherapy remains an exciting theoretical speculation largely unrealized to date. The major obstacle in designing effective peptide vaccines is our incapacity to scientifically define peptide immunogenicity. This mini-review schematically describes: 1) the available methods to identify epitopic peptides; 2) the sequence redundancy concept as a possible basis for peptide immunogenicity.
Keywords: Peptide-antibody interaction, antigenicity, immunogenicity, peptide features, redundant sequences
Current Drug Discovery Technologies
Title: Peptimmunology: Immunogenic Peptides and Sequence Redundancy
Volume: 2 Issue: 4
Author(s): Darja Kanduc
Affiliation:
Keywords: Peptide-antibody interaction, antigenicity, immunogenicity, peptide features, redundant sequences
Abstract: Using short peptide fragments of proteins to elicit antibodies able to recognize the protein from which the peptide sequence was derived, is one of the main goals in immunotherapy today. Indeed, peptide-immunotherapy appears as an obliged way to obtain antibodies of predetermined specificity and exempt from the complications associated with whole cells/entire protein vaccines. However, effective peptide-immunotherapy remains an exciting theoretical speculation largely unrealized to date. The major obstacle in designing effective peptide vaccines is our incapacity to scientifically define peptide immunogenicity. This mini-review schematically describes: 1) the available methods to identify epitopic peptides; 2) the sequence redundancy concept as a possible basis for peptide immunogenicity.
Export Options
About this article
Cite this article as:
Kanduc Darja, Peptimmunology: Immunogenic Peptides and Sequence Redundancy, Current Drug Discovery Technologies 2005; 2 (4) . https://dx.doi.org/10.2174/157016305775202946
DOI https://dx.doi.org/10.2174/157016305775202946 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Topical and Transdermal Delivery of Drug-Loaded Nano/ Microsystems with Application of Physical Enhancement Techniques
Current Drug Targets Biomarkers in Silent Traumatic Brain Injury
Current Pharmaceutical Design Roles of Hypoxia During the Chondrogenic Differentiation of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Anti-Cancer Drug Design Using Natural and Synthetic Pharmacophores
Current Organic Chemistry Live Impedance Measurements and Time-lapse Microscopy Observations of Cellular Adhesion, Proliferation and Migration after Ionizing Radiation
Current Pharmaceutical Biotechnology Therapeutic Immunoconjugates. Which Cytotoxic Payload: Chemotherapeutic Drug (ADC) or Radionuclide (ARC) ?
Current Cancer Therapy Reviews Preclinical Evaluation of New Taxoids
Current Pharmaceutical Design Biologic Characteristics of Bone Marrow Mesenchymal Stem Cells in Myelodysplastic Syndromes
Current Stem Cell Research & Therapy The Urokinase Receptor and its Structural Homologue C4.4A in Human Cancer: Expression, Prognosis and Pharmacological Inhibition
Current Medicinal Chemistry Editorial (Hot Topic: Coming Back to Nature: Plants as a Vital Source of Pharmaceutically Important Metabolites – Part II A)
Current Medicinal Chemistry Adhesion Molecules in Lung Cancer: Implications in the Pathogenesis and Management
Current Pharmaceutical Design OPLS-DA as a Suitable Method for Selecting a Set of Gene Transcripts Discriminating RAS- and PTPN11-Mutated Cells in Acute Lymphoblastic Leukaemia
Combinatorial Chemistry & High Throughput Screening Environmental Exposure, and Other Behavioral Risk Factors in Breast Cancer
Current Cancer Therapy Reviews Prostate Cancer Prevention in the Developing World - What are we Waiting for?
Current Pharmacogenomics and Personalized Medicine Porphyrin-based Sensitizers in the Detection and Treatment of Cancer: Recent Progress
Current Medicinal Chemistry - Anti-Cancer Agents Current Issues in the Utility of Blood Oxygen Level Dependent MRI for the Assessment of Modulations in Tumor Oxygenation
Current Medical Imaging Targeting the Endocannabinoid System for the Treatment of Cancer – A Practical View
Current Topics in Medicinal Chemistry Mitochondrial and Nuclear Genes of Mitochondrial Components in Cancer
Current Genomics Drug Nanocarriers and Functional Nanoparticles: Applications in Cancer Therapy
Current Drug Delivery Medical Treatment of Hirsutism in Women
Current Medicinal Chemistry